Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,836 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.
Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC. Aust S, et al. Among authors: berger a. Int J Gynecol Pathol. 2013 May;32(3):269-76. doi: 10.1097/PGP.0b013e31826a63f8. Int J Gynecol Pathol. 2013. PMID: 23518910
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R. Pils D, et al. Among authors: berger a. Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011. Epub 2013 Oct 28. Eur J Cancer. 2014. PMID: 24176298
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J. Baum J, et al. Among authors: berger a. Int J Gynecol Cancer. 2021 May;31(5):713-720. doi: 10.1136/ijgc-2020-002023. Epub 2021 Feb 9. Int J Gynecol Cancer. 2021. PMID: 33563640
A comparison of four technologies for detecting p53 aggregates in ovarian cancer.
Heinzl N, Koziel K, Maritschnegg E, Berger A, Pechriggl E, Fiegl H, Zeimet AG, Marth C, Zeillinger R, Concin N. Heinzl N, et al. Among authors: berger a. Front Oncol. 2022 Sep 8;12:976725. doi: 10.3389/fonc.2022.976725. eCollection 2022. Front Oncol. 2022. PMID: 36158680 Free PMC article.
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R. Concin N, et al. Among authors: berger a. Clin Cancer Res. 2005 Dec 1;11(23):8372-83. doi: 10.1158/1078-0432.CCR-05-0899. Clin Cancer Res. 2005. PMID: 16322298
3,836 results